Figure 3
From: RNA quantification using gold nanoprobes - application to cancer diagnostics
Au-nanoprobe detection of the BCR-ABL fusion gene sequence. (A) Colorimetric assay (above) and respective spectrophotometry (below) relative to the detection of synthetic BCR-ABL oligonucleotide target. Oligonucleotides with BCR or ABL sequence only (showing 50% complementarity) were used as controls and an unrelated target (showing 100% non-complementarity to the Au-nanoprobe) as negative control. (B) Detection of BCR-ABL in total RNA from K562 cell line, HL-60 cell line and human PBMC (harboring 50% complementary targets to the nanoprobe) and S. cerevisiae cells (100% non-complementary). Nanoprobe aggregation as measured by ratio of AUC500 nm-560 nm/AUC570 nm-630 nm. The dashed line represents the threshold of 1 considered for discrimination between Positive and Negative. The error bars represent the standard deviation from three independent assays.